CAR-T Cell Therapy at Fox Chase Cancer Center

Established in 1904, Fox Chase was the first cancer hospital in the United States, and is a founding member of the National Comprehensive Cancer Network (NCCN). Research has been at the heart of Fox Chase Cancer Center since the hospital opened more than a century ago.

Fox Chase research programs provide essential benefits to patients because of the close collaboration between scientists and physicians. The center continues to lead the field with seminal scientific discoveries that have key translational implications. In the past five years, they have discovered a new tumor suppressor syndrome; identified the medulloblastoma cell of origin and the role of ribosomal proteins in leukemogenesis; developed prognostic gene signatures in bladder cancer; demonstrated the efficacy of a targeted agent, ceritinib, in mutated/resistant non-small cell lung cancer; and increased cervical cancer screening rates in underserved populations.